Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma : ESES vienna presentation

Langenbeck's Archives of Surgery

Volumn 395, Issue 7, 2010, Pages 877-883

  Musholt, Thomas J ^a   Schönefeld, Sonja ^a   Schwarz, Christina H ^a   Watzka, Felix M ^a   Musholt, Petra B ^a   Fottner, Christian ^a   Weber, Matthias M ^a   Springer, Erik ^a   Schad, Arno ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

BRAF; Endocrine surgery; NTRK1; Papillary thyroid carcinoma; Prognosis; RET PTC

Indexed keywords

B RAF KINASE; PROTEIN RET; PROTEIN TYROSINE KINASE A; THYROGLOBULIN;

ADULT; AGE; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; DNA EXTRACTION; FEMALE; FROZEN SECTION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA; TUMOR GROWTH;

ADENOCARCINOMA, PAPILLARY; ADULT; AGED; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; FROZEN SECTIONS; GENE REARRANGEMENT; GERMANY; HUMANS; INTRAOPERATIVE CARE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, TRKA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 78149407730     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-010-0682-6     Document Type: Article

References (27)

1. F Basolo R Giannini C Monaco, et al. 2002 Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma Am J Pathol 160 247 254 1:CAS:528: DC%2BD38XnvFegtg%3D%3D 11786418
2. C Durante E Puxeddu E Ferretti, et al. 2007 BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism J Clin Endocrinol Metab 92 2840 2843 1:CAS:528:DC%2BD2sXotVyltL8%3D 10.1210/jc.2006-2707 17488796 (Pubitemid 47037399)
3. R Elisei C Ugolini D Viola, et al. 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study J Clin Endocrinol Metab 93 3943 3949 1:CAS:528:DC%2BD1cXht1Gmur3O 10.1210/jc.2008-0607 18682506
4. C Espadinha JR Santos LG Sobrinho, et al. 2009 Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency Clin Endocrinol 70 629 635 1:CAS:528:DC%2BD1MXkt12gtLo%3D 10.1111/j.1365-2265.2008.03376.x
5. L Fugazzola E Puxeddu N Avenia, et al. 2006 Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature Endocr-Relat Cancer 13 455 464 1:STN:280:DC%2BD283pslGmtQ%3D%3D 10.1677/erc.1.01086 16728573 (Pubitemid 43886668)
6. H Guan M Ji R Bao, et al. 2009 Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer J Clin Endocrinol Metab 94 1612 1617 1:CAS:528:DC%2BD1MXlvVCqt70%3D 10.1210/jc.2008-2390 19190105
7. YC Henderson TD Shellenberger MD Williams, et al. 2009 High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma Clin Cancer Res 15 485 491 1:CAS:528:DC%2BD1MXlvFektQ%3D%3D 10.1158/1078-0432.CCR-08-0933 19147753
8. Y Ito H Yoshida R Maruo, et al. 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients Endocr J 56 89 97 1:CAS:528:DC%2BD1MXlvVWgtrg%3D 10.1507/endocrj.K08E-208 18840924
9. E Kebebew J Weng J Bauer, et al. 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer Ann Surg 246 466 470 10.1097/SLA. 0b013e318148563d 17717450 discussion 470-461
10. SK Kim KH Song SD Lim, et al. 2009 Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis Thyroid 19 137 141 10.1089/thy.2008. 0144 19014278
11. JH Lee ES Lee YS Kim 2007 Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis Cancer 110 38 46 10.1002/cncr.22754 17520704 (Pubitemid 46986416)
12. X Lee M Gao Y Ji, et al. 2009 Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma Ann Surg Oncol 16 240 245 10.1245/s10434-008-0233-3 19034577
13. J Lima V Trovisco P Soares, et al. 2004 BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas J Clin Endocrinol Metab 89 4267 4271 1:CAS:528:DC%2BD2cXnslWhsLo%3D 10.1210/jc.2003-032224 15356020 (Pubitemid 39244424)
14. C Lupi R Giannini C Ugolini, et al. 2007 Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma J Clin Endocrinol Metab 92 4085 4090 1:CAS:528:DC%2BD2sXhtlartb7E 10.1210/jc.2007-1179 17785355 (Pubitemid 350074715)
15. W Moses J Weng E Khanafshar, et al. 2010 Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation J Surg Res 160 179 183 1:CAS:528:DC%2BC3cXltF2qtr8%3D 10.1016/j.jss.2009.05.031 19765726
16. PB Musholt F Imkamp R Von Wasielewski, et al. 2003 RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hurthle cell carcinomas? Surgery 134 881 889 10.1016/j.surg.2003.08.003 14668719 discussion 889 (Pubitemid 38010732)
17. TJ Musholt PB Musholt N Khaladj, et al. 2000 Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma Surgery 128 984 993 1:STN:280:DC%2BD3M%2FnsFemsg%3D%3D 10.1067/msy.2000.110845 11114633
18. G Oler JM Cerutti 2009 High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes Cancer 115 972 980 1:CAS:528:DC%2BD1MXjs1Kjurs%3D 10.1002/cncr.24118 19152441
19. SY Park YJ Park YJ Lee, et al. 2006 Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci Cancer 107 1831 1838 1:CAS:528:DC%2BD28Xht1Cms7bK 10.1002/cncr.22218 16983703 (Pubitemid 44582952)
20. MA Pierotti P Vigneri I Bongarzone 1998 Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas Recent Results Cancer Res 154 237 247 1:CAS:528:DyaK1cXmvFyrsL0%3D 10027004
21. G Riesco-Eizaguirre I Rodriguez A De La Vieja, et al. 2009 The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer Cancer Res 69 8317 8325 1:CAS:528:DC%2BD1MXhtlantr3P 10.1158/0008-5472.CAN-09-1248 19861538
22. G Salvatore G Chiappetta YE Nikiforov, et al. 2005 Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations Eur J Cancer 41 816 821 1:CAS:528:DC%2BD2MXitF2isbs%3D 10.1016/j.ejca.2005.01.004 15763659 (Pubitemid 40342564)
23. M Santoro M Papotti G Chiappetta, et al. 2002 RET activation and clinicopathologic features in poorly differentiated thyroid tumors J Clin Endocrinol Metab 87 370 379 1:CAS:528:DC%2BD38XntVyrsw%3D%3D 10.1210/jc.87.1.370 11788678 (Pubitemid 34084717)
24. MR Sapio D Posca A Raggioli, et al. 2007 Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings Clin Endocrinol 66 678 683 1:CAS:528:DC%2BD2sXlvFKlu78%3D 10.1111/j.1365-2265.2007.02800.x (Pubitemid 46699541)
25. MR Sapio D Posca G Troncone, et al. 2006 Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA) Eur J Endocrinol 154 341 348 1:CAS:528:DC%2BD28XitlGltL4%3D 10.1530/eje.1.02072 16452550
26. G Tallini M Santoro M Helie, et al. 1998 RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes Clin Cancer Res 4 287 294 1:CAS:528:DyaK1cXhtlSmsL8%3D 9516913
27. KT Tang CH Lee 2010 BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications J Chin Med Assoc 73 113 128 1:CAS:528:DC%2BC3cXls12lurg%3D 10.1016/S1726-4901(10)70025-3 20230995